XBiotech Welcomes Addition of Senior Vice President Corporate Development & General Counsel
AUSTIN, Texas, April 15, 2014 /PRNewswire/ -- XBiotech announced today that Robert Lindsey has joined the Company as Senior Vice President Corporate Development & General Counsel. Mr. Lindsey joins XBiotech from Dell where he served as Legal Director. In that capacity, Mr. Lindsey acted as the sole securities counsel for Dell and was the primary attorney responsible for the treasury, accounting, investor relations, corporate communications and internal audit groups. Most recently, Mr. Lindsey played a key role in Dell's going private transaction, which was the largest technology leveraged buy-out to date. As a registered patent attorney, at Dell Mr. Lindsey also helped evaluate intellectual property in respect to M&A transactions.
Mr. Lindsey holds a B.A. in Chemistry from Harvard University and a J.D. from the University of Virginia. Previously, he was a member of the corporate and securities group of Gibson, Dunn and Crutcher, LLP, a global 1,100 member law firm, where he was involved in the issuance of billions of dollars of securities and advised dozens of Fortune 500 clients on corporate and SEC related matters. As a Chartered Financial Analyst (CFA), Mr. Lindsey also has significant non-legal finance experience.
Mr. Lindsey stated, "I am incredibly excited to be joining XBiotech given all of the remarkable developments occurring at the Company. From the wonderful promise of its lead product, which is currently in Phase III studies, to the amazing potential of the other True Human™ antibodies being continually identified and developed, to the astonishing breakthroughs in cost efficiencies for its proprietary manufacturing technology, XBiotech is poised to make not just one, but several extraordinary impacts on the biopharmaceutical industry."
John Simard, the Company's Chairman & CEO commented, "I am very happy to welcome Robert to the team. His broad experience and technical expertise—as well as his energy and creativity—aligns well with our innovative operations and business strategy. We expect he will take a leading role in helping shape the great things to come."
XBiotech is leading the commercialization of biological therapies—including the discovery and development of True Human™ antibodies. The Company's lead product candidate—in Phase III clinical studies—is a novel, breakthrough treatment for advanced colorectal cancer. XBiotech has also developed manufacturing technology to reduce infrastructure needs, lessen capital requirements and reduce lead times for biological drugs, ushering in a new era for cost and development efficiency in the biopharmaceutical industry.